Continue Reading
Full article on Yahoo Finance
Akari Therapeutics Announces ADS Ratio Change
Market Intelligence Analysis
AI-Powered 94% HUGGINGFACE-PROSUSAI/FINBERT
Why This Matters
FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.
Sentiment
Neutral
AI Confidence
94%
Time Horizon
Short Term
Affected Symbols
Article Context
Note: This is a brief excerpt for context. Click below to read the full article on the original source.
TAMPA, Fla. and LONDON, March 17, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced that the Company will change the ratio of its American Depositary Shares (ADSs) to ordinary shares from one ADS representing two thousand (2,000) ordinary shares to a new ratio of one ADS representing eighty thousand (80,000) ordinary shares. The ratio change is ex
AI Breakdown
Summary
FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.
Time Horizon
Short Term
Original article published by
Yahoo Finance
on March 17, 2026.
Analysis and insights provided by AnalystMarkets AI.
Analysis and insights provided by AnalystMarkets AI.